| Literature DB >> 35954909 |
Diego Fernández-Lázaro1,2, Cesar I Fernandez-Lazaro3, Jesús Seco-Calvo4,5, Evelina Garrosa6, David P Adams7, Juan Mielgo-Ayuso8.
Abstract
Tribulus terrestris L. (TT) is a plant used in traditional Chinese medicine, Ayurvedic medicine, and sports nutrition to improve health and performance. However, no conclusive evidence exists about the potential beneficial effects of TT on sport and health biomarkers in physically active adults. Based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and the modified McMaster Critical Review Form for methodological quality assessment, we systematically reviewed studies indexed in Web of Science, Scopus, and PubMed, to assess the effects of TT on immunological, hematological, biochemical, renal, lipidic, hormonal behavior, and anti-inflammatory response in physically active adult males. Among 340 records identified in the search, a total of 7 studies met the inclusion and exclusion criteria. Overall, participants supplemented with TT displayed significant improvements in lipid profile. Inflammatory and hematological biomarkers showed moderate beneficial effects with no significant changes on renal biomarkers. No positive effects were observed on the immune system response. Additionally, no TT-induced toxicity was reported. In conclusion, there was no clear evidence of the beneficial effects of TT supplementation on muscle damage markers and hormonal behavior. More studies are needed to confirm the benefits of TT due to the limited number of studies available in the current literature.Entities:
Keywords: Tribulus terrestris; biomarkers; physically active adults; sport supplement; systematic review
Mesh:
Substances:
Year: 2022 PMID: 35954909 PMCID: PMC9368143 DOI: 10.3390/ijerph19159533
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Flow diagram depicting the identification and selection processes of relevant studies according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results of the methodological quality assessment of included studies—McMaster Critical Review Form for Quantitative Studies [21].
| Study | Item | Total | % | Quality Score | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ||||
| Ma et al., 2017 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 93.8 | E |
| Rogerson et al., 2007 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 15 | 93.8 | E |
| Fernández-Lázaro et al., 2021 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 100 | E |
| Talemi et al., 2021 [ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 100 | E |
| Milasius, et al., 2019 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 13 | 86.7 | VG |
| Poprzecki et al., 2005 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 86.7 | VG |
| Wilk et al., 2012 [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 13 | 86.7 | VG |
Abbreviations: 0 = not fulfilled criterion; 1 = fulfilled criterion; E = excellent; VG = very good. Item 1: study purpose; item 2: literature review; item 3: study design; item 4: blinding; item 5: sample description; item 6: sample size; item 7: ethics and consent; item 8: validity of outcomes; item 9: reliability of outcomes; item 10: intervention description; item 11: statistical significance; item 12: statistical analysis; item 13: clinical importance; item 14: conclusions; item 15: clinical implications; item 16: study limitations.
Characteristics of participants and supplementation protocols of the selected studies.
| Characteristics | Types | Study |
|---|---|---|
| Participants | Elite athletes | [ |
| Well-trained athletes | [ | |
| No regular training before the study | [ | |
| Supplementation product | Manufactured | [ |
| Registered product® | [ | |
| % Saponins of the supplementation product | 100% | [ |
| 60% | [ | |
| >40% | [ | |
| 40% | [ | |
| Total dose (mg) × day−1 | 1875 | [ |
| 1800–2700 | [ | |
| 1250 | [ | |
| 900–1800 | [ | |
| 770 | [ | |
| 500 | [ | |
| 450 | [ | |
| Duration | 12 weeks | [ |
| 6 weeks | [ | |
| 5 weeks | [ | |
| 4 weeks | [ | |
| 3 weeks–4 weeks (rest)–3 weeks | [ | |
| 2 weeks | [ | |
| 20 days | [ | |
| Dose schedule | After exercise and before going to sleep | [ |
| a.m. | [ | |
| a.m. and before going to sleep | [ | |
| a.m. and p.m. | [ | |
| No reported | [ |
Abbreviations: a.m. = ante meridiem; p.m. = post meridiem.
Studies included in the systematic review of the effect of Tribulus terrestris L. on hematological and biochemical markers, hormonal behavior, and oxidant response in healthy adults.
| First Author, Year of Publication, and Country | Study Design | Participants (Baseline Sample Size and Characteristics, Withdrawals, and Final Group Sample Size) | Intervention | Outcomes | Results | |
|---|---|---|---|---|---|---|
| Ma et al., 2017, | Random-ized, double-blind, placebo-controlled trial | 15 | 2 × 625 mg | BUN |
| |
|
|
| |||||
| ↓BUN | ↓BUN | |||||
|
| ||||||
|
|
| |||||
| ↑BUN | ||||||
| Rogerson et al., 2007, | Random-ized, double-blind, placebo-controlled trial | 22 | 450 mg/cap of | Testosterone/Epites-tosterone | ||
| Fernández-Lázaro et al., 2021, | Random-ized, single-blind, placebo-controlled trial | 30 | 2 caps × 385 mg | Testosterone | ||
| Talemi et al., 2021, | Random-ized, double-blind, placebo-controlled trial | 18 | 2 × 250 mg | IL-6 | ||
| Milasius, et al., 2019, | Placebo-controlled study | 32 | 3 × 625 mg | RCB Hb | ||
| Poprzecki et al., 2005, | Placebo-controlled study | 24 | “ | Testosterone | ||
| Wilk et al., 2012, | Random-ized, placebo-controlled trial | 14 | 1st 6 wk: 900 mg | Chol | ||
Abbreviations: ↑ = no significant increase; ↓ = no significant decrease; = no significant change. ↑* = significant increase; ↓* = significant decrease; CG = control group; IG = intervention group; wk = weeks; caps = capsules; TT = Tribulus Terrestris; DHT = dihydrotestosterone; IGF-1 = Insulin-like growth factor 1; IGFBP-3 = Insulin-like growth factor binding protein 3; GH = growth hormone; CK = creatine kinase; LDH = lactate dehydrogenase; Cr = creatinine; Ua = uric acid; BUN = blood urine nitrogen; RCB = red blood cells; HB = Hemoglobin; HCT = Hematocrit; ESR = erythrocyte sedimentation rate; MCV = mean corpuscular volume; WBC = white blood cells; LYM = lymphocytes MON = monocytes; GRAN = granulocytes; Chol = cholesterol; Tg = triglycerides; LDH-Chol = low-density lipoprotein; = males; HDL-Chol = high-density lipoprotein; IL-6 = interleukin 6; Hs-CRP = high-sensitivity C-reactive protein; y = years; kg = kilograms; m2 = square meters; mg = milligrams.